AquaBounty Technologies, Inc. entered into conversion agreements with the holders of all outstanding shares of its Series A Convertible Preferred Stock and…
AQUABOUNTY TECHNOLOGIES INC (AQB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously reported, on October 7, 2026, AquaBounty Technologies, Inc. (the “Company”) entered into conversion agreements with the holders of all outstanding shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and Series
How this was made
The 30-second read
Why it matters
The conversion increases the common share count by ~8.08 M, diluting existing shareholders and potentially pressuring the stock price.
Market read
Primary corporate action that changes share structure; traders may adjust positions based on dilution impact.
What to watch
Potential tax or accounting benefits for preferred holders and the possibility of future capital raises using the larger float.
Background
AquaBounty Technologies filed an 8‑K announcing the conversion of its Series A and B convertible preferred stock into common shares following SEC effectiveness of its S‑3 registration.
Ticker impact
SEC 8‑K reports automatic conversion of all Series A and B preferred shares into common stock, increasing the float to 13.29 M shares.
likely downward pressure as the market prices in dilution from the conversion
The filing is the first public disclosure of the conversion; no prior market pricing of the new share count existed.
Market effects
Adds to overall supply of biotech equities, modestly increasing sector float.
U.S. biotech market sees slight dilution; limited regional effect.
Minimal global impact; primarily a company‑specific corporate action.
Counterpoint
The conversion could improve liquidity and attract institutional investors, offsetting dilution concerns.
Key entities
- companyAquaBounty Technologies, Inc.
U.S. biotech firm specializing in genetically engineered salmon.



